2015 was a truly eventful year for Biocartis. It was marked by many transitions, which some see as a prelude to the company becoming a globally active market leader. Biocartis saw the source of its income shift from R&D to sales, as it was the first full financial year since the launch of its diagnostic platform Idylla™. In April 2015, the diagnostics producer delivered a stellar IPO, with the demand for Biocartis shares exceeding the availability by 6.5 times. 2016 is already off to a strong start: After recent collaboration deals with industry greats such as Merck and Amgen, Biocartis seems to be well on its way to becoming a force in the diagnostics market.
In contrast to the chemical industry, where many commercial processes are continuous processes, most processes in the biopharmaceutical industry are batch processes. The latter are generally slower and more expensive than their continuous counterparts. Continuous processes are also more reproducible, and the quality is more consistent. Despite these proven advantages, continuous processes are seldom found in the biopharmaceutical industry. As many improvements on process units are being developed, biopharmaceutical parties are becoming more and more aware of the added value of continuous bioprocessing. Pall Life Sciences presents a new downstream technology that is designed to increase purification efficiency using a continuous chromatography system.
In 2008, UGent spin-off ProDigest opened its doors. The company was built around a machine called the SHIME®, an in vitro model for the entire human gastrointestinal tract, complete with stomach and small and large intestines. The immediate interest from the food industry quickly made ProDigest a household name in its niche market. Since its establishment, ProDigest has significantly expanded its technology and activities and has taken on the pharmaceutical and veterinarian industries as additional partners.
2015 was a truly eventful year for Biocartis. It was marked by many transitions, which some see as a prelude to the company becoming a globally active market leader. Biocartis saw the source of its income shift from R&D to sales, as it was the first full financial year since the launch of its diagnostic platform Idylla™. In April 2015, the diagnostics producer delivered a stellar IPO, with the demand for Biocartis shares exceeding the availability by 6.5 times. 2016 is already off to a strong start: After recent collaboration deals with industry greats such as Merck and Amgen, Biocartis seems to be well on its way to becoming a force in the diagnostics market.
In contrast to the chemical industry, where many commercial processes are continuous processes, most processes in the biopharmaceutical industry are batch processes. The latter are generally slower and more expensive than their continuous counterparts. Continuous processes are also more reproducible, and the quality is more consistent. Despite these proven advantages, continuous processes are seldom found in the biopharmaceutical industry. As many improvements on process units are being developed, biopharmaceutical parties are becoming more and more aware of the added value of continuous bioprocessing. Pall Life Sciences presents a new downstream technology that is designed to increase purification efficiency using a continuous chromatography system.
In 2008, UGent spin-off ProDigest opened its doors. The company was built around a machine called the SHIME®, an in vitro model for the entire human gastrointestinal tract, complete with stomach and small and large intestines. The immediate interest from the food industry quickly made ProDigest a household name in its niche market. Since its establishment, ProDigest has significantly expanded its technology and activities and has taken on the pharmaceutical and veterinarian industries as additional partners.